Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Daryl L Davies, PhD

    TitleProfessor of Clinical Pharmacy and Director of Undergraduate Education
    SchoolSchool of Pharmacy
    DepartmentClinical Pharmacy and Pharmaceutical Econ. and Policy
    AddressPSC 506
    Health Sciences Campus
    Los Angeles California 90089-9121
    Phone+1 323 442 1427
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Daryl L. Davies, PhD, Professor of Clinical Pharmacy, Titus Family Department of Clinical Pharmacy, University of Southern California. In addition, he is the Director of the MS program in Management of Drug Development, in the International Center of Regulatory Science located in the School of Pharmacy. Dr. Davies earned his Bachelor and Master Degrees in Biology at California State University, Dominguez Hills. He earned his PhD in 1996 from the Department of Molecular Pharmacology and Toxicology at USC School of Pharmacy.
      Dr. Davies is the director of the Alcohol and Brain Research Laboratory at USC. His research revolves around the development of novel treatments for alcohol use disorders (AUDs). AUDs ranks third on the list of preventable causes of morbidity and mortality in the United States, having a major national impact affecting over 18 million people and causing over 100,000 deaths annually. The economic burden to society for AUDs is in excess of $220 billion annually which exceeds the costs of other leading preventable causes of death such as cigarette smoking and physical inactivity. Presently, pharmacotherapies, even in conjunction with psychosocial strategies, have had limited success in treating AUDs with approximately 70% of patients relapsing back into heavy drinking within one year. Finally, drug development for AUDs is a relatively young field compared to other diseases such as cancer, cardiovascular and psychiatric disorders. Therefore, the development of new treatments for AUDs represents an important unmet medical need.
      In response to this challenge, Dr. Davies and his team have focused on identifying molecular targets of alcohol action in the CNS. Recent findings from this line of investigation have resulted in the identification of specific targets for which therapeutic compounds have been designed and are currently under investigation. This multidisciplinary endeavor has brought together diverse but complementary group of scientists which include behavioral, pharmacological, electrophysiological, molecular, genetic, computational and medicinal chemistry expertise’s to maximize the potential for success. This team includes Drs. Ronald Alkana and Stan Louie (School of Pharmacy), Dr. Michael Neely (Keck School of Medicine), Dr. Nicos Petasis (Dornsife College LAS), Dr. Debra Finn (Oregon Health & Science University), and Dr. James Trudell (Stanford).


      Collapse ORNG Applications 
      Collapse Websites
      Collapse In The News

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Huynh N, Arabian N, Naito A, Louie S, Jakowec MW, Asatryan L, Davies D. Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Neuropharmacology. 2016 Sep 15; 113(Pt A):60-70. PMID: 27641072.
        View in: PubMed
      2. Xu J, Bernstein AM, Wong A, Lu XH, Khoja S, Yang XW, Davies D, Micevych P, Sofroniew MV, Khakh BS. P2X4 Receptor Reporter Mice: Sparse Brain Expression and Feeding-Related Presynaptic Facilitation in the Arcuate Nucleus. J Neurosci. 2016 Aug 24; 36(34):8902-20. PMID: 27559172.
        View in: PubMed
      3. Khoja S, Shah V, Garcia D, Asatryan L, Jakowec MW, Davies D. Role of purinergic P2X4 receptors in regulating striatal dopamine homeostasis and dependent behaviors. J Neurochem. 2016 Oct; 139(1):134-48. PMID: 27402173.
        View in: PubMed
      4. Guizzetti M, Davies D, Egli M, Finn DA, Molina P, Regunathan S, Robinson DL, Sohrabji F. Sex and the Lab: An Alcohol-Focused Commentary on the NIH Initiative to Balance Sex in Cell and Animal Studies. Alcohol Clin Exp Res. 2016 Jun; 40(6):1182-91. PMID: 27154003.
        View in: PubMed
      5. Roche DJ, Yardley MM, Lunny KF, Louie SG, Davies D, Miotto K, Ray LA. A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder. Alcohol Clin Exp Res. 2016 Jun; 40(6):1312-20. PMID: 27087145.
        View in: PubMed
      6. Huynh N, Arabian N, Lieu D, Asatryan L, Davies D. Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals. J Vis Exp. 2016; (109). PMID: 27078261.
        View in: PubMed
      7. Asatryan L, Khoja S, Rodgers KE, Alkana RL, Tsukamoto H, Davies D. Chronic ethanol exposure combined with high fat diet up-regulates P2X7 receptors that parallels neuroinflammation and neuronal loss in C57BL/6J mice. J Neuroimmunol. 2015 Aug 15; 285:169-79. PMID: 26198936.
        View in: PubMed
      8. Yardley MM, Huynh N, Rodgers KE, Alkana RL, Davies D. Oral delivery of ivermectin using a fast dissolving oral film: Implications for repurposing ivermectin as a pharmacotherapy for alcohol use disorder. Alcohol. 2015 Sep; 49(6):553-9. PMID: 26095588.
        View in: PubMed
      9. Helms CM, Bell RL, Bennett AJ, Davies D, Chester JA, Kosten TA, Leeman RF, Panicker S, Platt DM, Weiner JL, Edwards S. The importance of animals in advancing research on alcohol use disorders. Alcohol Clin Exp Res. 2015 Apr; 39(4):575-8. PMID: 25833015.
        View in: PubMed
      10. Naito A, Muchhala KH, Asatryan L, Trudell JR, Homanics GE, Perkins DI, Davies D, Alkana RL. Glycine and GABAA Ultra-Sensitive Ethanol Receptors as Novel Tools for Alcohol and Brain Research. Mol Pharmacol. 2014 Dec; 86(6):635-46. PMID: 25245406.
        View in: PubMed
      11. Yardley MM, Neely M, Huynh N, Asatryan L, Louie SG, Alkana RL, Davies D. Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans. Neuroreport. 2014 Sep 10; 25(13):1018-23. PMID: 25004078.
        View in: PubMed
      12. Franklin KM, Asatryan L, Jakowec MW, Trudell JR, Bell RL, Davies D. P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders. Front Neurosci. 2014; 8:176. PMID: 25009459.
        View in: PubMed
      13. Wyatt LR, Finn DA, Khoja S, Yardley MM, Asatryan L, Alkana RL, Davies D. Contribution of P2X4 Receptors to Ethanol Intake in Male C57BL/6 Mice. Neurochem Res. 2014 Jun; 39(6):1127-39. PMID: 24671605.
        View in: PubMed
      14. Asatryan L, Yardley MM, Khoja S, Trudell JR, Hyunh N, Louie SG, Petasis NA, Alkana RL, Davies D. Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders. Int J Neuropsychopharmacol. 2014 Jun; 17(6):907-16. PMID: 24451653.
        View in: PubMed
      15. Olsen RW, Li GD, Wallner M, Trudell JR, Bertaccini EJ, Lindahl E, Miller KW, Alkana RL, Davies D. Structural models of ligand-gated ion channels: sites of action for anesthetics and ethanol. Alcohol Clin Exp Res. 2014 Mar; 38(3):595-603. PMID: 24164436.
        View in: PubMed
      16. Popova M, Trudell J, Li K, Alkana R, Davies D, Asatryan L. Tryptophan 46 is a site for ethanol and ivermectin action in P2X4 receptors. Purinergic Signal. 2013 Dec; 9(4):621-32. PMID: 23817978.
        View in: PubMed
      17. Wyatt LR, Godar SC, Khoja S, Jakowec MW, Alkana RL, Bortolato M, Davies D. Sociocommunicative and sensorimotor impairments in male P2X4-deficient mice. Neuropsychopharmacology. 2013 Sep; 38(10):1993-2002. PMID: 23604007.
        View in: PubMed
      18. Bortolato M, Yardley MM, Khoja S, Godar SC, Asatryan L, Finn DA, Alkana RL, Louie SG, Davies D. Pharmacological insights into the role of P2X4 receptors in behavioural regulation: lessons from ivermectin. Int J Neuropsychopharmacol. 2013 Jun; 16(5):1059-70. PMID: 23174033.
        View in: PubMed
      19. Davies D, Bortolato M, Finn DA, Ramaker MJ, Barak S, Ron D, Liang J, Olsen RW. Recent Advances in the Discovery and Preclinical Testing of Novel Compounds for the Prevention and/or Treatment of Alcohol Use Disorders. Alcohol Clin Exp Res. 2012 Jun 4. PMID: 22671690.
        View in: PubMed
      20. Yardley MM, Wyatt L, Khoja S, Asatryan L, Ramaker MJ, Finn DA, Alkana RL, Huynh N, Louie SG, Petasis NA, Bortolato M, Davies D. Ivermectin reduces alcohol intake and preference in mice. Neuropharmacology. 2012 Aug; 63(2):190-201. PMID: 22465817.
        View in: PubMed
      21. Perkins DI, Trudell JR, Asatryan L, Davies D, Alkana RL. Charge and Geometry of Residues in the Loop 2 ß Hairpin Differentially Affect Agonist and Ethanol Sensitivity in Glycine Receptors. J Pharmacol Exp Ther. 2012 May; 341(2):543-51. PMID: 22357974.
        View in: PubMed
      22. Howard RJ, Slesinger PA, Davies D, Das J, Trudell JR, Harris RA. Alcohol-binding sites in distinct brain proteins: the quest for atomic level resolution. Alcohol Clin Exp Res. 2011 Sep; 35(9):1561-73. PMID: 21676006.
        View in: PubMed
      23. Asatryan L, Nam HW, Lee MR, Thakkar MM, Saeed Dar M, Davies D, Choi DS. Implication of the purinergic system in alcohol use disorders. Alcohol Clin Exp Res. 2011 Apr; 35(4):584-94. PMID: 21223299.
        View in: PubMed
      24. Ostrovskaya O, Asatryan L, Wyatt L, Popova M, Li K, Peoples RW, Alkana RL, Davies D. Ethanol is a fast channel inhibitor of P2X4 receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):171-9. PMID: 21212160.
        View in: PubMed
      25. Xu L, Li Y, Haworth IS, Davies D. Functional role of the intracellular loop linking transmembrane domains 6 and 7 of the human dipeptide transporter hPEPT1. J Membr Biol. 2010 Dec; 238(1-3):43-9. PMID: 21104182.
        View in: PubMed
      26. Asatryan L, Popova M, Perkins D, Trudell JR, Alkana RL, Davies D. Ivermectin antagonizes ethanol inhibition in purinergic P2X4 receptors. J Pharmacol Exp Ther. 2010 Sep 1; 334(3):720-8. PMID: 20543096.
        View in: PubMed
      27. Perkins DI, Trudell JR, Crawford DK, Alkana RL, Davies D. Molecular targets and mechanisms for ethanol action in glycine receptors. Pharmacol Ther. 2010 Jul; 127(1):53-65. PMID: 20399807.
        View in: PubMed
      28. Popova M, Asatryan L, Ostrovskaya O, Wyatt LR, Li K, Alkana RL, Davies D. A point mutation in the ectodomain-transmembrane 2 interface eliminates the inhibitory effects of ethanol in P2X4 receptors. J Neurochem. 2010 Jan; 112(1):307-17. PMID: 19878433.
        View in: PubMed
      29. Xu L, Haworth IS, Kulkarni AA, Bolger MB, Davies D. Mutagenesis and cysteine scanning of transmembrane domain 10 of the human dipeptide transporter. Pharm Res. 2009 Oct; 26(10):2358-66. PMID: 19685173.
        View in: PubMed
      30. Perkins DI, Trudell JR, Crawford DK, Asatryan L, Alkana RL, Davies D. Loop 2 structure in glycine and GABA(A) receptors plays a key role in determining ethanol sensitivity. J Biol Chem. 2009 Oct 2; 284(40):27304-14. PMID: 19656948.
        View in: PubMed
      31. Crawford DK, Perkins DI, Trudell JR, Bertaccini EJ, Davies D, Alkana RL. Roles for loop 2 residues of alpha1 glycine receptors in agonist activation. J Biol Chem. 2008 Oct 10; 283(41):27698-706. PMID: 18658152.
        View in: PubMed
      32. Asatryan L, Popova M, Woodward JJ, King BF, Alkana RL, Davies D. Roles of ectodomain and transmembrane regions in ethanol and agonist action in purinergic P2X2 and P2X3 receptors. Neuropharmacology. 2008 Oct; 55(5):835-43. PMID: 18639563.
        View in: PubMed
      33. Xiao C, Zhou C, Li K, Davies D, Ye JH. Purinergic type 2 receptors at GABAergic synapses on ventral tegmental area dopamine neurons are targets for ethanol action. J Pharmacol Exp Ther. 2008 Oct; 327(1):196-205. PMID: 18583548.
        View in: PubMed
      34. Perkins DI, Trudell JR, Crawford DK, Alkana RL, Davies D. Targets for ethanol action and antagonism in loop 2 of the extracellular domain of glycine receptors. J Neurochem. 2008 Aug; 106(3):1337-49. PMID: 18485105.
        View in: PubMed
      35. Li K, Xu L, Kulkarni AA, Perkins DI, Haworth IS, Davies D. Ethanol inhibits functional activity of the human intestinal dipeptide transporter hPepT1 expressed in Xenopus oocytes. Alcohol Clin Exp Res. 2008 May; 32(5):777-84. PMID: 18336632.
        View in: PubMed
      36. Crawford DK, Trudell JR, Bertaccini EJ, Li K, Davies D, Alkana RL. Evidence that ethanol acts on a target in Loop 2 of the extracellular domain of alpha1 glycine receptors. J Neurochem. 2007 Sep; 102(6):2097-109. PMID: 17561937.
        View in: PubMed
      37. Links JL, Kulkarni AA, Davies D, Lee VH, Haworth IS. Cysteine scanning of transmembrane domain three of the human dipeptide transporter: implications for substrate transport. J Drug Target. 2007 Apr; 15(3):218-25. PMID: 17454359.
        View in: PubMed
      38. Kulkarni AA, Davies D, Links JS, Patel LN, Lee VH, Haworth IS. A charge pair interaction between Arg282 in transmembrane segment 7 and Asp341 in transmembrane segment 8 of hPepT1. Pharm Res. 2007 Jan; 24(1):66-72. PMID: 17009102.
        View in: PubMed
      39. Davies D, Asatryan L, Kuo ST, Woodward JJ, King BF, Alkana RL, Xiao C, Ye JH, Sun H, Zhang L, Hu XQ, Hayrapetyan V, Lovinger DM, Machu TK. Effects of ethanol on adenosine 5'-triphosphate-gated purinergic and 5-hydroxytryptamine receptors. Alcohol Clin Exp Res. 2006 Feb; 30(2):349-58. PMID: 16441284.
        View in: PubMed
      40. Davies D, Kochegarov AA, Kuo ST, Kulkarni AA, Woodward JJ, King BF, Alkana RL. Ethanol differentially affects ATP-gated P2X(3) and P2X(4) receptor subtypes expressed in Xenopus oocytes. Neuropharmacology. 2005 Aug; 49(2):243-53. PMID: 15993446.
        View in: PubMed
      41. Woodward JJ, Nowak M, Davies D. Effects of the abused solvent toluene on recombinant P2X receptors expressed in HEK293 cells. Brain Res Mol Brain Res. 2004 Jun 18; 125(1-2):86-95. PMID: 15193425.
        View in: PubMed
      42. Davies D, Crawford DK, Trudell JR, Mihic SJ, Alkana RL. Multiple sites of ethanol action in alpha1 and alpha2 glycine receptors suggested by sensitivity to pressure antagonism. J Neurochem. 2004 Jun; 89(5):1175-85. PMID: 15147510.
        View in: PubMed
      43. Uchiyama T, Kulkarni AA, Davies D, Lee VH. Biophysical evidence for His57 as a proton-binding site in the mammalian intestinal transporter hPepT1. Pharm Res. 2003 Dec; 20(12):1911-6. PMID: 14725353.
        View in: PubMed
      44. Davies D, Alkana RL. Benzodiazepine agonist and inverse agonist coupling in GABAA receptors antagonized by increased atmospheric pressure. Eur J Pharmacol. 2003 May 23; 469(1-3):37-45. PMID: 12782183.
        View in: PubMed
      45. Davies D, Trudell JR, Mihic SJ, Crawford DK, Alkana RL. Ethanol potentiation of glycine receptors expressed in Xenopus oocytes antagonized by increased atmospheric pressure. Alcohol Clin Exp Res. 2003 May; 27(5):743-55. PMID: 12766618.
        View in: PubMed
      46. Davies D, Machu TK, Guo Y, Alkana RL. Ethanol sensitivity in ATP-gated P2X receptors is subunit dependent. Alcohol Clin Exp Res. 2002 Jun; 26(6):773-8. PMID: 12068244.
        View in: PubMed